Table 1.
The trend analysis of the weighted prevalence of MASLD in the U.S. population from 2001 to 2018.
| Characters | 2001–2002 (n = 1854) |
2003–2004 (n = 1737) |
2005–2006 (n = 1647) |
2007–2008 (n = 1520) |
2009–2010 (n = 1701) |
2011–2012 (n = 1496) |
2013–2014 (n = 1564) |
2015–2016 (n = 1398) |
2017–2018 (n = 1135) |
p-Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Total | 26.21 (23.14, 29.29) |
23.75 (19.84, 27.66) |
26.88 (23.30, 30.47) |
27.33 (23.94, 30.72) |
25.93 (23.22, 28.64) |
26.24 (22.35, 30.13) |
24.70 (22.23, 27.17) |
29.53 (26.57, 32.49) |
36.04 (32.13, 39.96) |
<0.001 |
| Sex | ||||||||||
| Male | 31.86 (26.20, 37.52) |
31.17 (27.85, 34.50) |
33.48 (29.39, 37.57) |
33.76 (29.70, 37.82) |
32.79 (28.97, 36.61) |
28.52 (23.74, 33.30) |
26.19 (22.10, 30.29) |
35.55 (29.95, 41.15) |
40.48 (33.77, 47.20) |
0.211 |
| Female | 20.39 (16.05, 24.72) |
16.18 (10.82, 21.54) |
19.92 (15.37, 24.47) |
20.90 (16.37, 25.43) |
19.17 (15.45, 22.89) |
24.15 (18.33, 29.98) |
23.29 (20.30, 26.27) |
23.78 (20.28, 27.27) |
31.79 (25.62, 37.95) |
<0.001 |
| Race | ||||||||||
| Mexican | 34.28 (28.15, 40.41) |
28.31 (19.94, 36.68) |
34.37 (29.45, 39.28) |
43.42 (38.03, 48.81) |
39.38 (33.22, 45.53) |
41.00 (33.12, 48.87) |
34.90 (27.39, 42.41) |
42.30 (33.44, 51.17) |
50.56 (41.80, 59.32) |
0.001 |
| White | 27.26 (23.84, 30.67) |
25.03 (20.31, 29.75) |
28.85 (24.41, 33.30) |
27.89 (24.06, 31.73) |
26.33 (22.95, 29.72) |
26.18 (20.70, 31.66) |
25.66 (22.17, 29.15) |
29.89 (26.05, 33.74) |
38.03 (33.03, 43.03) |
0.006 |
| Black | 16.71 (13.00, 20.42) |
13.48 (9.82, 17.14) |
13.77 (10.44, 17.11) |
13.19 (9.15, 17.23) |
16.49 (10.67, 22.31) |
17.81 (12.61, 23.00) |
16.45 (11.40, 21.51) |
18.43 (14.33, 22.53) |
20.61 (15.98, 25.24) |
0.013 |
| Other | 21.66 (14.27, 29.06) |
21.20 (11.49, 30.90) |
21.44 (11.46, 31.42) |
27.49 (22.86, 32.11) |
21.57 (16.09, 27.05) |
24.43 (19.10, 29.76) |
19.63 (15.72, 23.54) |
30.22 (25.69, 34.76) |
31.01 (23.65, 38.37) |
0.042 |
| BMI | ||||||||||
| <25 | 3.67 (2.02, 5.31) |
2.73 (1.06, 4.39) |
2.11 (0.91, 3.31) |
2.64 (0.95,4.33) |
2.73 (1.38, 4.07) |
1.86 (0.42, 3.31) |
1.89 (0.31, 3.46) |
3.07 (1.15, 4.98) |
5.56 (2.55, 8.56) |
0.590 |
| ≥25 | 42.65 (38.94, 46.37) |
36.15 (31.88, 40.42) |
41.90 (36.37, 47.43) |
42.48 (37.27, 47.68) |
43.27 (39.41, 47.13) |
40.71 (35.23, 46.20) |
38.62 (34.79, 42.44) |
42.06 (38.88, 45.24) |
48.80 (43.52, 54.09) |
0.041 |
| Diabetes mellitus | ||||||||||
| No | 22.08 (19.12, 25.04) |
19.99 (16.11, 23.86) |
22.09 (18.34, 25.85) |
22.17 (18.21, 26.13) |
21.57 (18.84, 24.30) |
21. 29 (17.21, 25.37) |
19.65 (17.07, 22.23) |
22.80 (19.11, 26.48) |
28.23 (23.78, 32.67) |
0.081 |
| Yes | 73.74 (64.68, 82.80) |
61.79 (54.69, 68.90) |
66.71 (60.20, 73.22) |
66.56 (57.92, 75.20) |
61.33 (53.87, 68.78) |
67. 85 (59.83,75.88) |
64.20 (58.10, 70.30) |
65.79 (58.18, 73.40) |
78.76 (72.30, 85.21) |
0.151 |
| Hypertension | ||||||||||
| No | 17.27 (13.98, 20.56) |
15.36 (13.14, 17.57) |
17.66 (14.34, 20.99) |
18.86 (15.62, 22.11) |
17.22 (15.08, 19.36) |
17.07 (13.09, 21.05) |
17.31 (14.61, 20.01) |
20.28 (16.15, 24.42) |
24.88 (18.86, 30.89) |
0.010 |
| Yes | 49.13 (39.56, 58.70) |
40.99 (33.84, 48.15) |
47.68 (42.21, 53.15) |
46.29 (40.26, 52.32) |
48.33 (42.58, 54.08) |
48.65 (40.94, 56.36) |
40.16 (36.48, 43.85) |
46.55 (42.15, 50.95) |
55.31 (48.10, 62.53) |
0.261 |
| Hyperlipidemia | ||||||||||
| No | 6.74 (4.07, 9.42) |
10.27 (6.92, 13.62) |
11.11 (6.95, 15.27) |
7.83 (5.04, 10.62) |
11.43 (8.19, 14.67) |
6.58 (4.46, 8.70) |
8.72 (5.95, 11.49) |
12.26 (7.57, 16.94) |
14.88 (8.91, 20.84) |
0.056 |
| Yes | 34.98 (31.62, 38.35) |
29.96 (25.53, 34.38) |
34.76 (30.48, 39.04) |
36.22 (32.21, 40.24) |
33.92 (30.99, 36.85) |
35.97 (30.84, 41.10) |
33.75 (31.18, 36.32) |
38.31 (33.87, 42.75) |
46.48 (42.25, 50.71) |
<0.001 |
Data were presented as weighted prevalence (%) and 95% CI. MASLD = Metabolic dysfunction-associated steatotic liver disease; BMI = body mass index, CI = confidence intervals.